|
JP3785932B2
(ja)
*
|
1998-05-25 |
2006-06-14 |
日本新薬株式会社 |
核酸含有複合体製剤の製造方法
|
|
AU776150B2
(en)
*
|
1999-01-28 |
2004-08-26 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
|
|
EP1097993A3
(en)
*
|
1999-11-05 |
2004-01-07 |
National Institute of Advanced Industrial Science and Technology |
Functional ribozyme chimeric molecules capable of sliding
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
EP1478992A4
(en)
*
|
2002-02-07 |
2007-03-21 |
Univ Utah Res Found |
METHOD FOR PRODUCING AND USING A TREATMENT PROTOCOL
|
|
US20040180438A1
(en)
*
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
|
CA2487274A1
(en)
|
2002-05-06 |
2003-11-13 |
Nucleonics Inc. |
Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
|
|
WO2003106636A2
(en)
*
|
2002-06-14 |
2003-12-24 |
Mirus Corporation |
Novel methods for the delivery of polynucleotides to cells
|
|
US20050239728A1
(en)
*
|
2002-07-31 |
2005-10-27 |
Pachuk Catherine J |
Double stranded rna structures and constructs, and methods for generating and using the same
|
|
WO2004073631A2
(en)
*
|
2003-02-14 |
2004-09-02 |
Combinatorx, Incorporated |
Combination therapy for the treatment of neoplasms
|
|
DK2270162T3
(en)
|
2003-06-12 |
2019-01-21 |
Alnylam Pharmaceuticals Inc |
PRESERVED HBV AND HCV SEQUENCES USED FOR GEN-SILENCING
|
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
|
CA2824308A1
(en)
|
2004-09-24 |
2006-04-06 |
Alnylam Pharmaceuticals, Inc. |
Targeting opposite strand replication intermediates of single-stranded viruses by rnai
|
|
WO2006069064A2
(en)
|
2004-12-22 |
2006-06-29 |
Nucleonics, Inc. |
Conserved hbv and hcv sequences useful for gene silencing
|
|
AU2006272555B2
(en)
|
2005-07-25 |
2012-03-08 |
Aptevo Research And Development Llc |
B-cell reduction using CD37-specific and CD20-specific binding molecules
|
|
CN105837690A
(zh)
*
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
DK2041270T3
(da)
|
2006-07-13 |
2014-01-27 |
Wyeth Llc |
Fremstilling af glycoproteiner
|
|
DK2094086T3
(da)
|
2006-11-08 |
2013-11-25 |
Veritas Bio LLC |
Indgivelse in vivo af dobbeltstrenget rna til en målcelle
|
|
WO2009023386A2
(en)
*
|
2007-07-06 |
2009-02-19 |
Trubion Pharmaceuticals, Inc. |
Binding peptides having a c-terminally disposed specific binding domain
|
|
NZ603059A
(en)
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
DK2427472T3
(en)
|
2009-05-05 |
2016-09-12 |
Miragen Therapeutics |
Lipophilic polynukleotidkonjugater
|
|
MA33488B1
(fr)
|
2009-06-08 |
2012-08-01 |
Miragen Therapeutics |
Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
|
|
RS55544B1
(sr)
|
2010-04-01 |
2017-05-31 |
Pharmanest Ab |
Termogelirajuće anestetičke kompozicije
|
|
CN103492569B
(zh)
|
2010-11-05 |
2020-04-07 |
米拉根医疗公司 |
碱基经修饰的寡核苷酸
|
|
EP2652151A2
(en)
|
2010-12-15 |
2013-10-23 |
Miragen Therapeutics |
Microrna inhibitors comprising locked nucleotides
|
|
AU2012242761A1
(en)
|
2011-04-12 |
2013-10-31 |
Beth Israel Deaconess Medical Center, Inc. |
Micro-RNA inhibitors and their uses in disease
|
|
EP2755663A4
(en)
|
2011-09-13 |
2015-10-07 |
Ottawa Hospital Res Inst |
MicroRNA Inhibitors
|
|
EP2864482A4
(en)
|
2012-06-21 |
2016-02-10 |
Miragen Therapeutics Inc |
OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN
|
|
MX364814B
(es)
|
2013-03-15 |
2019-05-08 |
Miragen Therapeutics Inc |
Nucleosidos biciclicos unidos en puente.
|
|
WO2015073707A1
(en)
|
2013-11-15 |
2015-05-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating heart failure with agonists of hypocretin receptor 2
|
|
WO2015074010A2
(en)
|
2013-11-18 |
2015-05-21 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for cardiac regeneration
|
|
WO2016022536A2
(en)
|
2014-08-04 |
2016-02-11 |
MiRagen Therapeutics, Inc. |
Inhibitors of myh7b and uses thereof
|
|
CN107108685B
(zh)
|
2014-09-08 |
2020-10-20 |
米拉根医疗股份有限公司 |
miR-29模拟物及其用途
|
|
HK1249108A1
(zh)
|
2015-01-20 |
2018-10-26 |
米拉根医疗股份有限公司 |
Mir-92抑制剂及其用途
|
|
MX368314B
(es)
|
2015-06-05 |
2019-09-27 |
Miragen Therapeutics Inc |
Inhibidores del mir-155 para tratar linfoma cutáneo de células t (ctcl).
|
|
HK1251480A1
(zh)
|
2015-09-21 |
2019-02-01 |
Aptevo Research And Development Llc |
Cd3结合多肽
|
|
US10357543B2
(en)
|
2015-11-16 |
2019-07-23 |
Ohio State Innovation Foundation |
Methods and compositions for treating disorders and diseases using Survival Motor Neuron (SMN) protein
|
|
WO2017222911A1
(en)
|
2016-06-20 |
2017-12-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Circular rnas and their use in immunomodulation
|
|
UY37376A
(es)
|
2016-08-26 |
2018-03-23 |
Amgen Inc |
Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
|
|
ES2659845B1
(es)
|
2016-09-19 |
2019-01-04 |
Univ Valencia |
Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
|
|
AR113490A1
(es)
|
2017-12-12 |
2020-05-06 |
Amgen Inc |
CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
|
|
CN111918968B
(zh)
|
2018-03-14 |
2023-11-24 |
贝斯以色列女执事医疗中心 |
Micro-RNA 22的抑制剂
|
|
CA3121510A1
(en)
|
2018-12-10 |
2020-06-18 |
Amgen Inc. |
Rnai constructs for inhibiting pnpla3 expression and methods of use thereof
|
|
SG11202105900UA
(en)
|
2018-12-10 |
2021-07-29 |
Amgen Inc |
CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
|
|
SG11202113112WA
(en)
|
2019-05-30 |
2021-12-30 |
Amgen Inc |
Rnai constructs for inhibiting scap expression and methods of use thereof
|
|
US20220340911A1
(en)
|
2019-08-13 |
2022-10-27 |
Amgen Inc. |
Rnai constructs for inhibiting slc30a8 expression and methods of use thereof
|
|
JP7827623B2
(ja)
|
2019-12-09 |
2026-03-10 |
アムジエン・インコーポレーテツド |
ＬＰＡ発現を阻害するためのＲＮＡｉコンストラクト及び方法
|
|
WO2021234607A1
(en)
|
2020-05-20 |
2021-11-25 |
St. Jude Children's Research Hospital |
Detection of alzheimer's disease using specific biomarkers
|
|
US20230279399A1
(en)
|
2020-06-01 |
2023-09-07 |
Amgen Inc. |
Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof
|
|
EP3929295A1
(en)
|
2020-06-26 |
2021-12-29 |
Universitat Pompeu Fabra |
Artificial rnas for modulating rna fragments
|
|
EP4196584A2
(en)
|
2020-08-13 |
2023-06-21 |
Amgen Inc. |
Rnai constructs and methods for inhibiting marc1 expression
|
|
KR20230104200A
(ko)
|
2020-11-05 |
2023-07-07 |
암젠 인크 |
LPA-표적화된 RNAi 작제물을 이용하여 죽상경화성 심혈관질환을 치료하는 방법
|
|
WO2023278295A1
(en)
|
2021-06-29 |
2023-01-05 |
The Broad Institute, Inc. |
Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
|
|
US20250011779A1
(en)
|
2021-10-05 |
2025-01-09 |
Amgen Inc. |
Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds
|
|
CA3235262A1
(en)
|
2021-10-22 |
2023-04-27 |
Amgen Inc. |
Rnai constructs for inhibiting gpam expression and methods of use thereof
|
|
CA3262515A1
(en)
|
2022-07-25 |
2024-02-01 |
Amgen Inc. |
ARNI CONSTRUCTIONS AND METHODS FOR INHIBITING FAM13A EXPRESSION
|
|
EP4353823A1
(en)
|
2022-10-12 |
2024-04-17 |
Resalis Therapeutics S.r.l. |
Inhibitors of micro-rna 22
|
|
KR20250119645A
(ko)
|
2022-12-16 |
2025-08-07 |
암젠 인크 |
Ttr 발현을 억제하기 위한 rnai 구성체 및 이의 사용 방법
|
|
WO2025260042A1
(en)
|
2024-06-14 |
2025-12-18 |
Amgen Inc. |
Rnai constructs and methods for inhibiting cnr1 expression
|
|
WO2026006275A2
(en)
|
2024-06-26 |
2026-01-02 |
Amgen Inc. |
Rnai constructs and methods for inhibiting expression of inhbe
|